Darin [ph]'s questions to IGM Biosciences (IGMS) leadership • Q4 2019
Question
Darin [ph] from Jefferies asked about expectations for the IGM-2323 data presentation at the 2020 ASH conference, specifically which dose cohorts might be included. He also questioned the manufacturing yield improvements for IGM-2323 and the assumptions underlying the company's stated 12-month clinical supply.
Answer
CEO Fred Schwarzer and Chief Medical Officer Dan Chen stated that while the goal is to have dosed the 1,000 mg cohort by ASH, the data presented will depend on enrollment pace and follow-up time. Chief Scientific Officer Bruce Keyt reported that manufacturing yields have approximately doubled since the first run, making them competitive with bispecific IgGs. Keyt and Chen confirmed the 12-month supply calculation is robust, assuming dosing up to 1,000 mg for 10-12 doses, and is sufficient for the Phase 1 trial.